Mark Stroh

2.4k total citations · 1 hit paper
55 papers, 1.9k citations indexed

About

Mark Stroh is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Mark Stroh has authored 55 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 15 papers in Molecular Biology and 11 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Mark Stroh's work include Monoclonal and Polyclonal Antibodies Research (10 papers), Cancer Immunotherapy and Biomarkers (9 papers) and HER2/EGFR in Cancer Research (7 papers). Mark Stroh is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (10 papers), Cancer Immunotherapy and Biomarkers (9 papers) and HER2/EGFR in Cancer Research (7 papers). Mark Stroh collaborates with scholars based in United States, United Kingdom and Spain. Mark Stroh's co-authors include Raymond C. Stevens, Moungi G. Bawendi, John P. Zimmer, Rakesh K. Jain, Yinthai Chan, Jonathan S. Steckel, Kenneth S. Cohen, Edward B. Brown, Dan G. Duda and Tatyana Levchenko and has published in prestigious journals such as Advanced Materials, Nature Medicine and Nature Materials.

In The Last Decade

Mark Stroh

52 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo

2005 322 citations Mark Stroh, John P. Zimmer et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Stroh United States	19	727	398	368	260	228	55	1.9k
Gary V. Martinez United States	29	1.5k 2.0×	480 1.2×	636 1.7×	353 1.4×	491 2.2×	48	3.1k
Hongbin Sun China	21	1.0k 1.4×	202 0.5×	423 1.1×	228 0.9×	97 0.4×	54	1.9k
Il Minn United States	29	786 1.1×	549 1.4×	135 0.4×	292 1.1×	756 3.3×	70	2.2k
Haiming Luo China	27	698 1.0×	171 0.4×	303 0.8×	458 1.8×	326 1.4×	47	1.7k
Mar Orzáez Spain	31	1.7k 2.3×	257 0.6×	346 0.9×	474 1.8×	70 0.3×	93	2.7k
Sylwia Rodziewicz‐Motowidło Poland	21	924 1.3×	163 0.4×	229 0.6×	128 0.5×	70 0.3×	109	1.6k
Per‐Ola Freskgård Sweden	24	1.5k 2.1×	288 0.7×	256 0.7×	234 0.9×	290 1.3×	41	2.6k
Zhanhong Wu United States	29	855 1.2×	687 1.7×	473 1.3×	664 2.6×	980 4.3×	79	3.1k
Ana M. García Italy	25	1.5k 2.1×	706 1.8×	359 1.0×	108 0.4×	191 0.8×	80	2.7k
Igor Barsukov United Kingdom	38	2.4k 3.3×	276 0.7×	222 0.6×	225 0.9×	148 0.6×	84	4.2k

Countries citing papers authored by Mark Stroh

Since Specialization

Citations

This map shows the geographic impact of Mark Stroh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Stroh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Stroh more than expected).

Fields of papers citing papers by Mark Stroh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Stroh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Stroh. The network helps show where Mark Stroh may publish in the future.

Co-authorship network of co-authors of Mark Stroh

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Stroh. A scholar is included among the top collaborators of Mark Stroh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Stroh. Mark Stroh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Phillips, Jonathan A., et al.. (2023). Clinical Pharmacology and Translational Considerations in the Development of CRISPR‐Based Therapies. Clinical Pharmacology & Therapeutics. 114(3). 591–603. 4 indexed citations

Johnson, Melissa L., Anthony B. El-Khoueiry, Navid Hafez, et al.. (2021). Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies. Clinical Cancer Research. 27(16). 4521–4530. 45 indexed citations

Claret, Laurent, Jin Y. Jin, Charles Ferté, et al.. (2018). A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non–Small Cell Lung Cancer Based on Early Tumor Kinetics. Clinical Cancer Research. 24(14). 3292–3298. 53 indexed citations

Stroh, Mark, et al.. (2016). Meta-analysis of published efficacy and safety data for docetaxel in second-line treatment of patients with advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology. 77(3). 485–494. 7 indexed citations

Lü, Dan, Tong Lu, Mark Stroh, et al.. (2016). A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities. Cancer Chemotherapy and Pharmacology. 77(3). 459–476. 41 indexed citations

Borin, Marie T., et al.. (2014). Onartuzumab with or without bevacizumab in combination with weekly paclitaxel does not prolong QTc or adversely affect other ECG parameters in patients with locally recurrent or metastatic triple-negative breast cancer. Cancer Chemotherapy and Pharmacology. 75(2). 401–410. 5 indexed citations

Gibson, Christopher R., Ping Lü, Zoe Barter, et al.. (2013). Using human recombinant UDP-glucuronosyltransferase isoforms and a relative activity factor approach to model total body clearance of laropiprant (MK-0524) in humans. Xenobiotica. 43(12). 1027–1036. 15 indexed citations

Stroh, Mark, et al.. (2013). Simultaneous Pharmacokinetic Model for Rolofylline and both M1-trans and M1-cis Metabolites. The AAPS Journal. 15(2). 498–504. 3 indexed citations

Stroh, Mark, Xiaodong Li, Deborah Panebianco, et al.. (2012). The minimal impact of food on the pharmacokinetics of ridaforolimus. Cancer Chemotherapy and Pharmacology. 70(1). 177–182. 4 indexed citations

10.

Stroh, Mark, John Palcza, Jacqueline B. McCrea, et al.. (2012). The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus. Cancer Chemotherapy and Pharmacology. 69(5). 1247–1253. 5 indexed citations

11.

Lush, Richard M., Amita Patnaik, Daniel M. Sullivan, et al.. (2012). A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 70(4). 567–574. 1 indexed citations

12.

Wei, Jie, Jeffrey J. Jones, Jing Kang, et al.. (2011). RNA-Induced Silencing Complex-Bound Small Interfering RNA Is a Determinant of RNA Interference-Mediated Gene Silencing in Mice. Molecular Pharmacology. 79(6). 953–963. 40 indexed citations

13.

Radziszewski, Waldemar, Eseng Lai, Mark Stroh, et al.. (2010). A Single Supratherapeutic Dose of Rolofylline Does Not Prolong the QTcF Interval in Healthy Volunteers. American Journal of Therapeutics. 17(1). 8–16. 1 indexed citations

14.

Stroh, Mark, Victor Dishy, Waldemar Radziszewski, et al.. (2010). The Effects of Multiple Doses of Rolofylline on the Single-Dose Pharmacokinetics of Midazolam in Healthy Subjects. American Journal of Therapeutics. 17(1). 53–60. 3 indexed citations

15.

Schwartz, Jules I., Mark Stroh, Bing Gao, et al.. (2009). Effects of Laropiprant, a Selective Prostaglandin D₂ Receptor 1 Antagonist, on the Pharmacokinetics of Rosiglitazone. Cardiovascular Therapeutics. 27(4). 239–245. 4 indexed citations

16.

Schwartz, Jules I., Fang Liu, Mark Stroh, et al.. (2009). Influence of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, on the Pharmacokinetics and Pharmacodynamics of Warfarin. American Journal of Therapeutics. 16(3). 215–223. 4 indexed citations

17.

Addy, Carol, C. Assaid, David Hreniuk, et al.. (2009). Single‐Dose Administration of MK‐0657, an NR2B‐Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moderate Parkinson's Disease. The Journal of Clinical Pharmacology. 49(7). 856–864. 51 indexed citations

18.

Stroh, Mark, John P. Zimmer, Dan G. Duda, et al.. (2005). Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nature Medicine. 11(6). 678–682. 322 indexed citations breakdown →

19.

Stroh, Mark, Warren R. Zipfel, Rebecca M. Williams, Watt W. Webb, & W. Mark Saltzman. (2003). Diffusion of Nerve Growth Factor in Rat Striatum as Determined by Multiphoton Microscopy. Biophysical Journal. 85(1). 581–588. 57 indexed citations

20.

Stroh, Mark. (1992). Inside Broccoli: A Weapon against Cancer. Science News. 141(12). 183–183. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact